Global Cancer Cachexia Market Report and Forecast 2023-2028 (2023)

Insights of the global cancer cachexia market

The global Cancer Cachexia market is projected to grow at a CAGR of 4.7% during the period 2023-2028.

Read more about this report-REQUEST A FREE SAMPLE PDF COPY

The global cancer cachexia market is likely to be driven by the increasing number of cachexia cases and advances in treatment systems.

The global cancer cachexia market is expected to be driven by the increase in cachexia cases and advances in modern treatment systems. North America, Europe and Japan are expected to be the main markets. Cases of cachexia are on the rise and the condition currently affects almost 1% of all patients. In recent years, there has been a growing understanding of the multifaceted nature of cachexia, particularly the role of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methods have failed in phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has shown early results.

Cachexia is a serious consequence of a variety of chronic diseases and is associated with poor quality of life. In advanced chronic heart failure, the incidence of cachexia ranges from 5 to 15 percent; in advanced cancer, the incidence of cachexia is between 50 and 80 percent. Many people with chronic kidney disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia later in life. Cachectic syndrome is one of the main causes of morbidity and mortality in cancer patients. Cancer cachexia has also been associated with decreased efficacy of chemotherapy, increased side effects, and discontinuation of treatment. Progressive cachexia indicates a poor prognosis with a shorter survival time and accounts for almost 20% of all cancer deaths. If there is a weight loss of 10% or more in 6 months, this may indicate the presence of cachexia. There is a direct correlation between cancer patient survival and the rate and magnitude of weight loss.

The cachectic syndrome has three stages: precachexia, cachexia, and refractory cachexia. Signs such as weight loss (less than 5%), anorexia, and glucose intolerance occur in the precachectic stage. The progression to cachexia depends on several factors, including systemic inflammation, the type and stage of the cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss is almost impossible due to active catabolism or the presence of cachectic factors. Patients with acute muscular atrophy are unlikely to benefit from treatments that target lean tissue and function. At this stage, therapy is aimed at relieving symptoms and reducing suffering rather than prolonging life.

Combination therapies with new drugs are promising; New drugs should stimulate the market

Cancer cachexia is currently incurable. Current therapies for cachexia involve a multidisciplinary approach; Combination therapy, which includes dietary modifications and exercise (when possible), has been incorporated into newer drugs such as megestrol acetate, medroxyprogesterone, ghrelin, and omega-3 fatty acids, among others. These treatments have been reported to result in better survival rates and quality of life. Advances in treatment systems and promising investigational drugs are expected to drive the market forward.

In 2021, Helsinn, the Swiss pharmaceutical manufacturer of high-quality products for the treatment of cancer and rare diseases, announced the first commercial launch of Adlumiz.^o(Anamorelin) for the treatment of cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan through its sister company Ono Pharmaceutical. adlumiz^o(Anamorelin), approved by the Japanese health authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in patients with cancer cachexia.

AVEO's AV-380 is a potent first-class humanized inhibitory IgG1 antibody directed to growth differentiation factor 15 (GDF15). Preclinical data suggest that GDF15 inhibition results in a shift from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia. In 2022, AVEO Oncology completed enrollment for its Phase I study in cachexia (in volunteers) in the United States (parenteral) (NCT04815551) and plans to initiate a Phase Ib study in cancer in mid-2022.

Global Cancer Cachexia Market Segmentation

Read more about this report-REQUEST A FREE SAMPLE PDF COPY

By therapeutics, the market is segmented into:

• progestins
• corticosteroids
• combination therapy
• Others

According to the mechanism of action, the market is classified into:

• appetite stimulant
• Weight Loss Stabilizers

By distribution channel, the market is segmented into:

• hospital pharmacy
• retail pharmacy
• online pharmacy

By region, the market is segmented into:

• North America
• Europa
• Pacific Asia
• Latin America
• Middle East and Africa

Read more about this report-REQUEST A FREE SAMPLE PDF COPY

Major Players in Global Cancer Cachexia Market

The report provides an in-depth analysis of the major market players, examining their capacity and the latest developments such as capacity expansions, facility conversions, and mergers and acquisitions:

• Merck & Co., Inc.
• Aphios Corporation
• Helsinn Healthcare SA
• AVEO Pharmaceuticals, Inc.
• Ono Pharmaceutical Co., Ltd.
• pfizer inc.
• Others

The EMR report provides an in-depth look at the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces Model.

*At Expert Market Research, we strive to provide you with up-to-date and accurate information at all times. The numbers shown in the description are indicative and may differ from the actual numbers in the final EMR report.

1. Introduction
2 Report coverage: key scope and segmentation
3 Report description
3.1 Market definition and prospects
3.2 Properties and Applications
3.3 Market analysis
3.4 Main actors
4 main assumptions
5 Summary
5.1 Summary
5.2 Main drivers
5.3 Main developments
5.4 Structure of the competition
5.5 Main industrial trends
6 Market overview
6.1 World
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cancer Cachexia Market Analysis
8.1 Major Industry Highlights
8.2 Global Cancer Cachexia Market (2018-2022)
8.3 Global Cancer Cachexia Market Forecast (2023-2028)
8.4 Global Cancer Cachexia Market by Therapeutics
8.4.1 Progestins
8.4.1.1 Market share
8.4.1.2 Historical evolution (2018-2022)
8.4.1.3 Forecast trend (2023-2028)
8.4.2 Corticosteroids
8.4.2.1 Market share
8.4.2.2 Historical evolution (2018-2022)
8.4.2.3 Forecast trend (2023-2028)
8.4.3 Combined therapy
8.4.3.1 Market share
8.4.3.2 Historical development (2018-2022)
8.4.3.3 Trend forecast (2023-2028)
8.4.4 Miscellaneous
8.5 Global Cancer Cachexia Market by Mechanism of Action
8.5.1 Appetite stimulant
8.5.1.1 Market share
8.5.1.2 Historical evolution (2018-2022)
8.5.1.3 Forecast trend (2023-2028)
8.5.2 Weight loss stabilizers
8.5.2.1 Market share
8.5.2.2 Historical evolution (2018-2022)
8.5.2.3 Forecast trend (2023-2028)
8.6 Global Cancer Cachexia Market by Distribution Channel
8.6.1 Hospital Pharmacy
8.6.1.1 Market share
8.6.1.2 Historical development (2018-2022)
8.6.1.3 Forecast trend (2023-2028)
8.6.2 Retail Pharmacy
8.6.2.1 Market share
8.6.2.2 Historical evolution (2018-2022)
8.6.2.3 Forecast trend (2023-2028)
8.6.3 Online Pharmacy
8.6.3.1 Market share
8.6.3.2 Historical development (2018-2022)
8.6.3.3 Forecast trend (2023-2028)
8.7 Global Cancer Cachexia Market by Regions
8.7.1 Market share
8.7.1.1 North America
8.7.1.2 Europa
8.7.1.3 Asia-Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical development (2018-2022)
9.1.2 Forecast trend (2023-2028)
9.1.3 Breakdown by country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europa
9.2.1 Historical development (2018-2022)
9.2.2 Trend forecast (2023-2028)
9.2.3 Breakdown by country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italia
9.2.3.5 Miscellaneous
9.3 Asia-Pacific
9.3.1 Historical development (2018-2022)
9.3.2 Trend Forecast (2023-2028)
9.3.3 Breakdown by country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 seconds
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Miscellaneous
9.4 Latin America
9.4.1 Historical development (2018-2022)
9.4.2 Trend Forecast (2023-2028)
9.4.3 Breakdown by country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Miscellaneous
9.5 Middle East and Africa
9.5.1 Historical development (2018-2022)
9.5.2 Forecast trend (2023-2028)
9.5.3 Breakdown by country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Miscellaneous
10 Market dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter's Five Forces Analysis
10.2.1 Provider's Power of Attorney
10.2.2 Purchasing power
10.2.3 Threat of new entrants
10.2.4 Rivalry Level
10.2.5 Threat of Substitutes
10.3 Main demand indicators
10.4 Main Price Indicators
11 competitive scenario
11.1 Market structure
11.2 Company profiles
11.2.1 Merck & Co., Inc.
11.2.1.1 General description of the company
11.2.1.2 Product portfolio
11.2.1.3 Demographic reach and achievements
11.2.1.4 Certifications
11.2.2 Aphios Corporation
11.2.2.1 General description of the company
11.2.2.2 Product portfolio
11.2.2.3 Demographic reach and achievements
11.2.2.4 Certifications
11.2.3 Helsinn Healthcare S.A.
11.2.3.1 General description of the company
11.2.3.2 Product portfolio
11.2.3.3 Demographic reach and achievements
11.2.3.4 Certifications
11.2.4 AVEO Pharmaceuticals, Inc.
11.2.4.1 Company Summary
11.2.4.2 Product portfolio
11.2.4.3 Demographic reach and achievements
11.2.4.4 Certifications
11.2.5 Ono Pharmaceutical Co., Ltd.
11.2.5.1 General description of the company
11.2.5.2 Product portfolio
11.2.5.3 Demographic reach and achievements
11.2.5.4 Certifications
11.2.6 Pfizer Inc.
11.2.6.1 Company Summary
11.2.6.2 Product portfolio
11.2.6.3 Demographic reach and achievements
11.2.6.4 Certifications
11.2.7 Miscellaneous
12 Industry events and developments

List of indexes and tables

1. Global Cancer Cachexia Market: Key Industry Insights, 2017 and 2021
2. Historic Global Cancer Cachexia Market: Breakdown by Therapeutic (USD Million), 2018-2022
3. Global Cancer Cachexia Market Forecast: Breakdown by Therapeutics (USD Million), 2023-2028
4. Global Historical Cancer Cachexia Market: Resolution by Mechanism of Action ($Mn), 2018-2022
5. Global Cancer Cachexia Market Forecast: Resolution By Mechanism Of Action (Million USD), 2023-2028
6. Historic Global Cancer Cachexia Market: Breakdown by Distribution Channel (Million USD), 2018-2022
7. Global Cancer Cachexia Market Forecast: Breakdown by Distribution Channel (Million USD), 2023-2028
8. Historic Global Cancer Cachexia Market: Breakdown by Region (USD Million), 2018-2022
9. Global Cancer Cachexia Market Forecast: Breakdown by Region (USD Million), 2023-2028
10. Historic North America Cancer Cachexia Market: Breakdown by Country (Million USD), 2018-2022
11. North America Cancer Cachexia Market Forecast: Breakdown by Country (Million USD), 2023-2028
12. Europe Historical Cancer Cachexia Market: Breakdown by Country (USD Million), 2018-2022
13. Europe Cancer Cachexia Market Forecast: Breakdown by Country (USD Million), 2023-2028
14. Asia Pacific Historic Cancer Cachexia Market: Breakdown by Country (USD Million), 2018-2022
15. Asia-Pacific Cancer Cachexia Market Forecast: Breakdown by Country (Million USD), 2023-2028
16. Historical Cancer Cachexia Market in Latin America: Breakdown by Country (Millions of dollars), 2018-2022
17. Latin America Cancer Cachexia Market Forecast: Breakdown by Country (Million USD), 2023-2028
18. Historic Middle East and Africa Cancer Cachexia Market: Breakdown by Country (Million US$), 2018-2022
19. Middle East and Africa Cancer Cachexia Market Forecast: Breakdown by Country (Million USD), 2023-2028
20. Structure of Global Cancer Cachexia Market